Welcome to our dedicated page for CureVac N.V. Ordinary Shares news (Ticker: CVAC), a resource for investors and traders seeking the latest updates and insights on CureVac N.V. Ordinary Shares stock.
CureVac N.V. (NASDAQ: CVAC) is a pioneering biopharmaceutical company based in Germany, known for its groundbreaking work in the field of messenger RNA (mRNA) technology. Founded in 2000 as a spin-off from the University of Tübingen, CureVac has developed a unique position as a leader in mRNA research and development. The company's core technology uses mRNA as a data carrier that instructs the human body to produce its own proteins capable of fighting a wide range of diseases, including cancer, infectious diseases, and rare genetic disorders.
CureVac's proprietary mRNA technology has a broad range of applications. In oncology, the company is developing both off-the-shelf and personalized cancer vaccines. Their off-the-shelf cancer vaccines target tumor antigens shared across different cancer types, while the personalized vaccines are tailored to individual patients based on their unique tumor profiles. CureVac has recently entered a collaboration with The University of Texas MD Anderson Cancer Center to further this mission.
In infectious disease, CureVac has partnered with pharmaceutical giant GSK to develop a suite of prophylactic vaccines. This includes second-generation COVID-19 vaccines and a promising seasonal influenza vaccine program. Recent Phase 2 interim data showed that CureVac's influenza vaccine candidates produce higher geometric mean titers against influenza A strains compared to licensed vaccines, though optimizations are ongoing for influenza B strains. Additionally, a new Phase 2 study has been initiated to further enhance the immune response against the relevant influenza B strain.
Financially, CureVac remains robust, with cash and cash equivalents amounting to €402.5 million at the end of 2023. The company's strategic initiatives, such as organizational redesign and partnerships, aim to extend this runway into the fourth quarter of 2025. As of late, CureVac has also achieved significant milestones in its clinical pipeline, which includes a move to Phase 2 studies for its H5N1 avian flu vaccine candidate and ongoing litigation to defend its intellectual property rights.
Overall, CureVac continues to push the boundaries of mRNA technology, with a deep clinical pipeline and strong collaborations to back its innovative discoveries. For more information, visit their official website at www.curevac.com.
CureVac N.V. (NASDAQ:CVAC) announced significant changes to its Supervisory Board. Dr. Ingmar Hoerr has withdrawn his candidacy due to ongoing health issues, while Dr. Timothy M. Wright has resigned to focus on personal endeavors. Both were recognized for their contributions to the company, with Hoerr credited for advancing mRNA technology. CureVac continues to develop transformative mRNA-based medicines and has a diverse clinical pipeline targeting vaccines, cancer therapies, and rare diseases. The company remains committed to its innovative approach in the biopharmaceutical sector.
CureVac (NASDAQ:CVAC) announced its second interim analysis of the HERALD study, which evaluated its COVID-19 vaccine candidate CVnCoV. Conducted across 10 countries with approximately 40,000 participants, the analysis revealed an interim efficacy of 47% against COVID-19; however, it did not meet the statistical success criteria. The safety profile remained favorable. Out of 134 assessed cases, 57% were due to variants of concern. The study is progressing towards a final analysis, with results shared with the European Medicines Agency (EMA). CureVac is also advancing second-generation vaccine candidates.
CureVac N.V. (NASDAQ:CVAC) announced the appointment of Klaus Edvardsen, MD, PhD, as Chief Development Officer, effective August 1, 2021. His extensive experience in clinical and product development, particularly in oncology, is expected to guide CureVac's transition into a fully integrated biopharmaceutical company. Edvardsen previously held senior roles at Merck KGaA and AstraZeneca, enhancing his capability to advance CureVac's mRNA technology and clinical pipeline. The company remains focused on mRNA therapeutics, including its COVID-19 vaccine candidate, CVnCoV.
CureVac announced promising preclinical results for its second-generation COVID-19 vaccine candidate, CV2CoV, developed in collaboration with GSK. The vaccine demonstrates high levels of antigen production and strong, fast-acting immune responses in rat models. Notably, CV2CoV elicited significant cross-neutralizing antibodies against variants of concern such as those from Denmark, the UK, and South Africa. The candidate is engineered for improved stability and efficacy, with clinical trials expected to commence in Q3 2021, aiming for broad protection against emerging strains.
CureVac N.V. (NASDAQ: CVAC) reported significant progress in its COVID-19 vaccine candidate CVnCoV, now in the final stage of clinical development with over 40,000 participants in a pivotal study across Europe and Latin America. The company anticipates interim efficacy data in Q2 2021. With a strong cash position of €1.32 billion as of December 31, 2020, and an additional $517.5 million raised in early 2021, CureVac is well-positioned for growth. Partnerships with Bayer, GSK, and the UK government aim to expedite vaccine development and expand production capacity to 1 billion doses by 2022.
CureVac N.V. (Nasdaq:CVAC) will announce its financial results and business updates for Q4 and the full year 2020 on April 15, 2021. A conference call and webcast will be held at 4:00 p.m. CET / 10:00 a.m. EST. Investors can access the webcast on the CureVac Investor Relations page. CureVac is focused on transformative medicines utilizing mRNA technology to create vaccines and therapies across various diseases. The company emphasizes its extensive experience in developing mRNA for medical applications.
CureVac N.V. (Nasdaq: CVAC) announced promising preclinical data for its COVID-19 vaccine candidate, CVnCoV, demonstrating protection against the SARS-CoV-2 variant B.1.351 (South African variant) in transgenic mice. The study showed that CVnCoV induced robust antibody responses, achieving full protection (100% survival) against both the original virus and the variant strain following a two-dose vaccination schedule. The vaccine effectively blocked viral replication in infected mice, underscoring its potential in combating emerging SARS-CoV-2 variants.
CureVac (Nasdaq:CVAC) is enhancing its late-stage clinical trials for its COVID-19 vaccine candidate, CVnCoV, in response to new variants. The pivotal HERALD Phase 2b/3 trial will now include select strains for a case-driven analysis. Additionally, a protocol amendment for the Phase 2a trial in older adults will add a secondary efficacy endpoint. CureVac aims for market authorization by Q2 2021 and anticipates data readouts from both trials in the same quarter.
CureVac and Novartis have signed an initial agreement for the manufacturing of CureVac's COVID-19 vaccine candidate, CVnCoV. Production is set to begin in Q2 2021, aiming for up to 50 million doses by the end of 2021, and an additional 200 million doses in 2022 at Novartis' Kundl site in Austria. This collaboration enhances CureVac's European manufacturing network, expected to boost capacity significantly. The agreement is part of CureVac's ongoing development of mRNA-based vaccines initiated in January 2020, with prior successful clinical trials.
CureVac N.V. (NASDAQ:CVAC) announced its participation in two upcoming virtual investor conferences: the Leerink 10th Annual Global Healthcare Conference on February 24, 2021, at 8:00 am EST, and the Credit Suisse 2021 London Global Healthcare Conference on March 2, 2021, at 12:00 pm GMT / 7:00 am EST. Interested parties can find event details and access presentation materials on CureVac's Investor Relations page. The company, based in Tübingen, Germany, specializes in mRNA technology, with over 20 years of experience.
FAQ
What is the current stock price of CureVac N.V. Ordinary Shares (CVAC)?
What is the market cap of CureVac N.V. Ordinary Shares (CVAC)?
What does CureVac N.V. do?
Where is CureVac headquartered?
Who are CureVac's notable partners?
What are CureVac's recent achievements in vaccine development?
How is CureVac financially positioned?
What is the role of mRNA in CureVac's technology?
What are CureVac's focus areas in oncology?
What are some challenges CureVac has faced?
What recent collaborations has CureVac entered into?
What is CureVac's latest financial result?
